The European Medicines Agency (EMA) on Thursday supported the use of Novavax’s COVID-19 shot as a booster for adults, in light of an anticipated increase in infections this winter.
The vaccine, Nuvaxovid, is designed to target the virus strain that originally emerged in China. The EMA recommendation is for people who have previously received Novavax or any other COVID vaccine.
On Thursday alone, EMA supported two separate COVID-19 vaccine boosters updated to target the Omicron variant of the virus.
Developed by Moderna and the Pfizer and BioNTech team, the new so-called bivalent footage against the BA.1 version of Omicron and the original virus was first discovered in China.
Novavax’s Nuvaxovid has launched successfully after the first batch of COVID-19 snapshots – including images from Moderna, Pfizer-BioNTech, AstraZeneca and Johnson & Johnson – were approved in different parts of the world .
The hope is that Nuvaxovid will encourage skeptics of some of the newer mRNA technology-based injections to vaccinate, as Nuvaxovid is based on technology that has been used for decades to fight diseases including hepatitis B and flu.
However, demand has fallen. Last month, US vaccine maker Novavax cut its annual revenue forecast in half due to limited primary vaccine demand.
Some experts have suggested that as a booster for people who have already received other vaccines, it could still offer the potential for broader spectrum protection.
(This story has not been edited by NDTV staff and was automatically generated from the syndication feed.)